Hepatitis B vaccine, adjuvanted has been approved in the European Union and in the Other Countries

Studies listed may include approved and non-approved uses, formulations or treatment regimens. Before prescribing any product mentioned in this Register, healthcare Professionals should consult prescribing information approved in their country (view UK and US information for Healthcare Professionals).

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.


Hepatitis B vaccine, adjuvanted studies

Select the study ID number to view the trial summary

Study IDPhaseTitle
105757 III A phase III, multicentric, multinational, controlled, randomised, open study comparing the immunogenicity, reactogenicity and safety of an investigational vaccination regimen to that of GlaxoSmithKline Biologicals’ adjuvanted hepatitis B vaccine, Fendrix®, administered according to 0, 1, 2, 6 months schedule, in hepatitis B naïve pre-dialysis, peritoneal dialysis and haemodialysis patients (>/ 15 years of age). Fendrix® (HBV): GlaxoSmithKline Biologicals’ adjuvanted hepatitis B vaccine